Anti-A33 Recombinant Antibody (HmAb A33) (CAT#: TAB-0626CLV)

Figure 1 Surface Plasmon resonance. Association and dissociation curves of A33 antibody preparations on an A33 antigen-coated biochip.

Deckert, P. M., Renner, C., Cohen, L. S., Jungbluth, A., Ritter, G., Bertino, J. R.,... & Welt, S. (2003). A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy. British journal of cancer, 88(6), 937.

Figure 2 A33scFv-CD-mediated cytotoxicity on A33 antigen-positive vs negative cells.

LIM1215 cells and HT29 cells were incubated with a dilution series of A33scFv-CD fusion protein and, after washing, with the 5-FC prodrug. Survival was measured by the MTT method as described. A33scFv-CD fusion protein from two different preparations was used on HT29 cells (▴ and ▾) and on LIM1215 cells (• and◆). As a control, a single, high concentration of A33scFv-GFP (□) was used instead of A33scFv-CD. Mean and s.d. of triplicate samples.

Deckert, P. M., Renner, C., Cohen, L. S., Jungbluth, A., Ritter, G., Bertino, J. R.,... & Welt, S. (2003). A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy. British journal of cancer, 88(6), 937.

Figure 3 MTT cytotoxicity blocking assay.

As a negative control, A33scFv-CD was used without subsequent prodrug incubation (▪), and 5-FU alone served as positive control (▴). In the complete ADEPT assay with subsequent 5-FC incubation as described in the text, cells were preincubated either with the "A33scFv-GFP" antibody (▫) or with hu3S193 as an isotypic control antibody (▾) for 1 h before the fusion protein was added. Mean and s.d. of triplicate samples.

Deckert, P. M., Renner, C., Cohen, L. S., Jungbluth, A., Ritter, G., Bertino, J. R.,... & Welt, S. (2003). A33scFv–cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy. British journal of cancer, 88(6), 937.